Effects of RG2833 (HDAC1/3 Inhibitor) on the gene expression of Male TgF344 Alzheimer’s disease Rat model.

We investigated the long-term therapeutic effects of oral administration of a brain-penetrant HDAC1/3 inhibitor RG2833 in a Fisher transgenic 344-AD (TgF344-AD) rat model of AD. We treated for 6 months, starting at 5 months of age administering the drug in rodent chow at ~30mg/kg of body weight. After treatment we performed experiments to show the effects of drug treatment on spatial memory deficits and gene expression.本研究针对Fisher转基因344-AD（TgF344-AD）大鼠阿尔茨海默病（Alzheimer Disease，AD）模型，探究了可透过血脑屏障的组蛋白去乙酰化酶1/3抑制剂（HDAC1/3 inhibitor）RG2833口服给药的长期治疗效果。研究于大鼠5月龄时启动给药，以约30mg/kg体重的剂量将药物掺入啮齿类动物饲料中进行投喂，持续给药时长为6个月。给药结束后，本研究开展相关实验以验证药物治疗对空间记忆缺陷及基因表达的影响。